Latex bead injection model useful for studying retinal ganglion cell loss

Article

A new model for latex bead injections demonstrates that this is a viable approach to increasing IOP and inducing loss of retinal ganglion cells in rats, said Rebecca M. Sappington, PhD, research fellow, Vanderbilt University, Vanderbilt Eye Institute, Nashville.

A new model for latex bead injections demonstrates that this is a viable approach to increasing IOP and inducing loss of retinal ganglion cells in rats, said Rebecca M. Sappington, PhD, research fellow, Vanderbilt University, Vanderbilt Eye Institute, Nashville.

Using a model adapted from earlier designs, Dr. Sappington and colleagues injected fluorescent latex beads 15 mm in diameter into the anterior chamber of one eye and saline into the other eye in a group of adult Norway Brown rats.

Investigators used a tonometer (Tono-Pen, Reichert Inc.) to measure IOP in awake rats and used the mean of 25 measurements to calculate changes over time. They also measured axonal area and loss of axons and performed histologic examinations. They were able to elevate IOP for up to at least 5 weeks by giving the rats two injections of beads; IOP levels increased by 30% to 40% over this period. A single injection reduced IOP about 30% over 2 weeks.

Investigators also observed that a 2.5-ml injection produced a slow rise in IOP, while a 5-ml injection produced a large initial increase. In addition, after 2 weeks of elevated IOP, eyes injected with the higher dose of latex beads showed a greater reduction in distal nerve retinal ganglion cells than in proximal nerve cells. In contrast, eyes that had been given the 5-ml injection of beads showed the same pattern of axon loss in the proximal and distal nerves, Dr. Sappington said. At 5 weeks, more severe axonal loss was again found in the distal nerve than in the proximal nerve in eyes that had received the smaller injection of beads. In eyes receiving the larger injection, the loss pattern remained consistent between the two types of nerves.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.